Immune checkpoint inhibitors for progressive multifocal leukoencephalopathy: Identifying relevant outcome factors.

Current data suggest that patients with PML under immunosuppressive therapy are less likely to respond to ICIs and raises the issue of the optimal management of irAEs during ICI treatment in this setting.